News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Barron's Deals and strategy
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Wells Fargo has reiterated its Buy rating for Spyre Therapeutics (SYRE.US), maintaining its price target at $115. This suggests continued confidence from Wells Fargo in the company's financial prospects and stock performance.
Spyre Therapeutics' chief legal officer, Heidy King-Jones, sold shares worth over $2.63 million on October 1, 2026, after exercising stock options. These transactions were executed under a Rule 10b5-1 trading plan. Despite the stock's significant surge over the past year, InvestingPro analysis suggests it โฆ
Cameron Turtle, CEO of Spyre Therapeutics Inc (SYRE), sold 15,000 shares of the company on October 1, 2026, at $92.01 per share. This transaction is part of a larger trend of insider selling at SYRE, with 30 insider sells and 0 buys over the โฆ
Spyre Therapeutics CEO Cameron Turtle sold 14,000 shares of SYRE stock for approximately $1.38 million on October 1, 2026, under a Rule 10b5-1 trading plan. This sale follows a significant 487% surge in the stock over the past year, though InvestingPro analysis suggests it's โฆ
Heidy King-Jones, Chief Legal Officer and Corporate Secretary of Spyre Therapeutics (SYRE), exercised options for 28,933 common shares at $14.50 per share on October 1, 2026. She subsequently sold these shares in five separate transactions under a Rule 10b5-1 trading plan, with weighted-average sale โฆ
Heidy King-Jones, an officer at Spyre Therapeutics (NASDAQ:SYRE), has filed a Form 144 to sell 29,335 shares of common stock, valued at over $2.6 million, under a pre-established Rule 10b5-1 trading plan. These shares will be acquired through stock option exercises. King-Jones has also โฆ
J.P. Morgan has initiated coverage on Spyre Therapeutics (SYRE.US) with a "Buy" rating. The investment bank has set a target price of $110 for the company's stock. This new rating and price target indicate a positive outlook from J.P. Morgan regarding Spyre Therapeutics' future โฆ
Heidy King-Jones, an officer at Spyre Therapeutics (SYRE), plans to sell 29,335 common shares worth approximately $2.61 million on October 1, 2026. This proposed sale follows two previous 10b5-1 sales by King-Jones in September 2026, totaling over $2.4 million. The shares were and will โฆ
J.P. Morgan initiated coverage on Spyre Therapeutics (SYRE) with an Overweight rating and a $110 price target for year-end 2027. Analyst Hardik Parikh highlighted the company's strong potential in treating inflammatory bowel disease (IBD) as the primary driver for the positive outlook. This news โฆ
Spyre Therapeutics (SYRE) stock is up 5.22% after positive Phase 2 SKYLINE data for its SPY003 drug, which met its primary endpoint for ulcerative colitis. Despite the strong clinical results, shares traded modestly lower initially, suggesting high market expectations and a "wait and see" โฆ
Spyre Therapeutics (SYRE) stock is trending up after positive Phase 2 SKYLINE trial data for SPY003 in ulcerative colitis, hitting its primary endpoint and de-risking its IBD pipeline. This win, combined with validated SPY001 and SPY002, establishes a multi-mechanism IBD platform. Despite strong data, โฆ
Spyre Therapeutics (SYRE) saw a 5.1% increase in its stock price, likely due to sustained investor confidence following positive Phase 2 clinical trial results for its ulcerative colitis treatment, SPY003. The company announced strong 12-week topline results in early September, meeting its primary endpoint โฆ
Spyre Therapeutics (SYRE) is a clinical-stage biotechnology company developing long-acting antibodies for inflammatory bowel disease (IBD) and rheumatic diseases. The company's pipeline includes investigational antibodies SPY001, SPY002, SPY072, and SPY003, designed for infrequent subcutaneous dosing, and it is exploring rational combinations of these therapies. โฆ
JonesTrading has reaffirmed its Buy rating for Spyre Therapeutics (SYRE.US) and maintained its target price at $121. This indicates continued confidence from the firm in the company's prospects and valuation.
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States